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Natural killer cells are regulated by killer cell immunoglobulin-like receptor (KIR) interactions with HLA class I
ligands. Several models of natural killer cell reactivity have been associated with improved outcomes after mye-
loablative allogeneic hematopoietic cell transplantation (HCT), but this issue has not been rigorously addressed in
reduced-intensity conditioning (RIC) unrelated donor (URD) HCT. We studied 909 patients undergoing RIC-URD
HCT. Patients with acute myeloid leukemia (AML, n ¼ 612) lacking  1 KIR ligands experienced higher grade III
to IV acute graft-versus-host disease (GVHD) (HR, 1.6; 95% CI, 1.16 to 2.28; P ¼ .005) compared to those with all
ligands present. Absence of HLA-C2 for donor KIR2DL1was associatedwith higher grade II to IV (HR,1.4; P¼ .002)
and III to IV acuteGVHD (HR,1.5; P¼ .01) comparedwithHLA-C2þ patients. AML patientswith KIR2DS1þ, HLA-C2
homozygous donors had greater treatment-related mortality compared with others (HR, 2.4; 95% CI, 1.4 to 4.2;
P¼ .002)butdidnotexperience lower relapse. Therewerenosigniﬁcantassociationswithoutcomes forAMLwhendgments on page 1595.
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R.M. Sobecks et al. / Biol Blood Marrow Transplant 21 (2015) 1589e15961590assessing donor-activating KIRs or centromeric KIR content or for any donorerecipient KIR-HLA assessments in
patients withmyelodysplastic syndrome (n¼ 297). KIR-HLA combinations in RIC-URDHCT recapitulate some but
not all KIR-HLA effects observed in myeloablative HCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Disease relapse is a signiﬁcant cause of treatment failure
after allogeneic hematopoietic cell transplantation (HCT).
With reduced-intensity conditioning (RIC) approaches, in
particular, the graft-versus-leukemia (GVL) effect is critical
for successful outcomes in patients with advanced myeloid
malignancies. Therefore, strategies to optimize conditions for
achieving a GVL effect will improve outcomes of RIC HCT.
The GVL effect has been attributed to donor-derived
alloreactive immune cells, including T lymphocytes and
natural killer (NK) cells [1-4]. The function of NK cells is
regulated by inhibitory and activating signals mediated
through cell-surface receptors, including killer cell
immunoglobulin-like receptors (KIRs). HLA-C is the main
ligand for most inhibitory KIRs and is categorized into C1 and
C2 groups based on a polymorphism at residue 80 in the HLA
molecule [5]. Inhibitory KIR2DL2 and KIR2DL3 are speciﬁc
for the C1 ligand group, and inhibitory KIR2DL1 is speciﬁc for
the C2 ligand group. The inhibitory KIR3DL1 receptor is
speciﬁc for HLA molecules with the HLA-Bw4 epitope [6].
When inhibitory KIRs encounter self-HLA class I ligands
on target cells, they signal inhibition and establish tolerance
[4,7,8]. In contrast, lack of HLA class I ligand engagement of
inhibitory KIRs in the context of simultaneous activation
signaling permits NK activation and target cell cytotoxicity.
NK alloreactivity due to lack of self-class I ligand (“missing
self”) is evident in HLA-mismatched allogeneic HCT, the
clinical setting in which potent antileukemic effects of donor
NK cells ﬁrst became recognized [3]. Similarly, in HLA-
matched HCT, lack of a class I ligand in the recipient for
donor-inhibitory KIR (“missing ligand”) can also result in
lower acutemyeloid leukemia (AML) relapse after HCT [9,10].
Stimulation of speciﬁc activating KIRs can result in NK cell
killing [4,11]. Donor-activating KIR genotype has been re-
ported to inﬂuence post-transplant outcomes including
grade II to IV acute graft-versus-host disease (GVHD),
transplant-related mortality (TRM), relapse-free survival,
and overall survival [12-15]. Donor KIR2DS1 has been asso-
ciated with a lower relapse of AML after allogeneic HCT in an
HLA-C1edependent manner [15]. KIR group B haplotypes
[16,17], enriched for stimulatory KIR genes, have been re-
ported to be associated with less relapse and improved sur-
vival compared with KIR group A haplotypes, enriched for
inhibitory genes, in AML patients undergoing unrelated
donor (URD) HCT [18]. This association was strongest for
activating genes located in the centromeric (cen) region of
the KIR gene complex (ie, cen-B homozygosity). Interest-
ingly, effects of the activating KIRs are strongest in patients
with HLA-C1 ligand [15,19].
Donor HLA ligands are also important in NK cell licensing.
Lack of donor HLA ligand for cognate inhibitory KIR has been
associated with adverse survival due to disease progression
after URD HCT [20].
KIReHLA interactions have been reported to inﬂuence
outcomes of myeloablative haploidentical [3,21], HLA-
matched related donor [10,22], and URD [9,23,24] alloge-
neic HCT, particularly for AML patients. KIR-mediated effectsmay also inﬂuence outcomes after RIC for haploidentical and
umbilical cord blood transplants, although studied cohorts
were small [25,26]. In RIC allogeneic HCT, where both donor
and recipient hematopoiesis may coexist, the effect of
KIReHLA interactions on outcomes is not clear. We therefore
examined the various models of NK cell alloreactivity and
their associations with post-transplant outcomes among a
large cohort of 909 AML and myelodysplastic syndrome
(MDS) patients receiving an allograft from a 7/8 or 8/8
HLA-matched URD after RIC. We ﬁnd that speciﬁc
donorerecipient KIReHLA combinations are associated with
post-transplant outcomes, including some but not all previ-
ously observed in myeloablative HCT.
METHODS
Study Design
This retrospective study was designed to test the hypothesis that
donorerecipient KIReHLA interactions are associated with improved post-
transplant outcomes after RIC-URD allogeneic HCT for AML and MDS.
Clinical data were provided by the Center for International Blood and
Marrow Transplant Research (CIBMTR).
Patients and Donors
The study population included all AML andMDS patients reported to the
CIBMTR who received RIC allogeneic HCT from 1999 to 2007 from URDs
matched at 7 or 8 of the possible 8 alleles at HLA-A, -B, -C, and -DR loci and
who had samples stored in the National Marrow Donor Program (NMDP)
Research Repository. Transplant conditioning regimen intensity was deter-
mined according to the CIBMTR RIC Regimen Workshop criteria [27]. Some
patients had in vivo T cell depletion with either antithymocyte globulin or
alemtuzumab.
HLA and KIR Genotyping
HLA genotyping for patients and donors was performed through the
ongoing NMDP retrospective typing program as previously described [28].
KIR genotyping was performed retrospectively for donors through the
NMDP contract laboratory network using commercially available KIR gen-
otyping kits (Invitrogen, Canoga Park, CA and One Lambda, Grand Island,
NY) and/or DNA sequencing [29].
Data Sources
The CIBMTR is a combined research program of the Medical College of
Wisconsin and the NMDP. CIBMTR comprises a voluntary network of more
than 450 transplantation centers worldwide that contribute detailed data
on consecutive allogeneic and autologous HCT to a centralized statistical
center. Observational studies conducted by the CIBMTR are performed in
compliance with all applicable federal regulations pertaining to the pro-
tection of human research participants. Protected Health Information used
in the performance of such research is collected andmaintained in CIBMTR’s
capacity as a Public Health Authority under the HIPAA Privacy Rule. Addi-
tional details regarding the data source are as previously described [30].
Study Endpoints
The study endpoints included acute and chronic GVHD, relapse, TRM,
disease-free survival (DFS), and overall survival. TRM was deﬁned as death
in continuous remission of primary disease. This event was summarized by
the cumulative incidence estimate with relapse as a competing risk and
second transplant as a censoring event. Grades II to IV and III to IV acute
GVHD were deﬁned according to the Glucksberg scale [31]. Chronic GVHD
included the development of symptoms in any organ system fulﬁlling the
criteria of limited or extensive chronic GVHD [32]. These events were
summarized by the cumulative incidence estimate with death as a
competing risk and second transplant as a censoring event. Disease relapse
consisted of a clinical relapse of the primary disease as deﬁned by the
CIBMTR. The event was summarized by the cumulative incidence estimate
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Overall survival was deﬁned as time to death from any cause, and DFS was
determined from time to disease relapse or death.
Statistical Analysis
Cox proportional hazards models were used to examine the association
of donor KIR genotype with the hazard of failure for various time-to-event
outcomes of HCT (death from any cause, disease relapse, DFS, and death
without relapse). The assumption of proportional hazards for adjusted
clinical factors in the Cox model was tested using time-dependent cova-
riates. Factors that violated the proportional hazard assumption were
adjusted via stratiﬁcation. The multivariate models were built using a
stepwise forward/backward model selection approach, with the adjusted
clinical covariates being selected at the .05 signiﬁcance level.
The following variables were analyzed for their prognostic value on each
of the outcomes: patient characteristics (age, gender, Karnofsky perfor-
mance score, recipient race/ethnicity), disease characteristics (disease status
at transplantation), and transplant-related factors (time from diagnosis to
HCT, recipient cytomegalovirus status, hematopoietic graft type, transplant
conditioning regimen, GVHD prophylaxis, number of high-resolution HLA
matches, in vivo T cell depletion, and donor race/ethnicity). Adjustments for
multiple variables were performed for outcomes analysis for each model of
NK alloreactivity.
Patient-, disease-, and transplant-related factors were compared be-
tween groups using the chi-square test for categorical variables and the
Wilcoxon 2-sample test for continuous variables. Cumulative incidence es-
timates to account for competing risks were calculated for TRM, acute and
chronic GVHD, and disease relapse. DFS and survival curves were estimated
by the Kaplan-Meier method [33]. Each model of NK alloreactivity was
tested for all 7 outcomes with adjustments for the selected clinical cova-
riates. To adjust for multiple testing, KIR variables with P < .01 were
considered statistically signiﬁcant.
The main effects were assessed separately for patients with AML and for
those with MDS. The following mechanisms of NK alloreactivity were
evaluated:
1. Missing KIR ligand model: This model assessed the presence or
absence of recipient HLA ligands for cognate donor-inhibitory KIRs.
The presence/absence of HLA-Bw4, HLA-C1, and HLA-C2 KIR ligands
were segregated into the following groups: all ligands present versus
missing C1 ligand only versus missing C2 ligand only versus missing
Bw4 ligand only versus missing both Bw4 and C1 or C2. A 2-group
comparison between the presence of any missing ligand in the
recipient versus the presence of all ligands was also evaluated. This
model was also used to assess the presence or absence of speciﬁc
HLA-Bw4, HLA-C1, and HLA-C2 ligands in the recipient irrespective of
any other KIR ligand. Each ligand was evaluated separately from the
others, with pairwise comparisons between the presence and
absence of the KIR ligand. Donor KIR ligand absence was also
assessed to evaluate its potential impact on achievement of donor T
cell chimerism on a subset of patients who had this data available.
Cases were only included in this analysis if the chimerism studies
were performed with short tandem repeat or variable copy numbers
of tandem repeats methods.
2. Assessment of individual donor-activating KIRs: Each activating KIR
(KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, and KIR3DS1) was
evaluated separately from the others, with pairwise comparisons
between the presence and absence of the KIR gene in the donor.
3. Effects of KIR2DS1 and HLA-C background: KIR2DS1 presence versus
absence in the donor was assessed. KIR2DS1þ donors were then
further segregated based on presence or absence of HLA-C1 in the
donor, as previously described [15].
4. Donor centromeric KIR content: This model assessed the presence of
speciﬁc centromeric KIR combinations previously reported to in-
crease survival. Donors were classiﬁed as homozygous for cen-B
haplotype (KIR2DS2þ and/or KIR2DL2þ, KIR2DL3), homozygous
for the cen-A haplotype (KIR2DL3þ, KIR2DL1þ, KIR2DL2, KIR2DS2),
or heterozygous for centromeric haplotypes A and B. These groupings
were assessed for a cumulative dose effect of cen-B (cen-AA versus
cen-AB versus cen-BB).
RESULTS
Patient and Donor Characteristics
Among the 909 patients in this study population, there
were 612 AML and 297 MDS subjects (Table 1). These
included 478 AML and 234 MDS donorerecipient pairs that
were 8/8 HLA-matched and 134 AML and 63 MDS that were7/8 HLA-matched. Among the AML and MDS patients, 29%
and 32%, respectively, were Bw6/Bw6 (therefore missing
Bw4 ligand); 41% and 40%, respectively, were C1C1 (missing
C2 ligand); and 14% and 9%, respectively, were C2C2 (missing
C1 ligand). One hundred eighty-one (30%) of the AML pa-
tients had an antecedent hematologic disorder, including 107
with MDS (17%). The median age was 56 years (range, 20 to
74), and the hematopoietic graft sources included 169 bone
marrow (19%) and 740 peripheral blood progenitor cells
(81%). RIC consisted of 210 total body irradiation-based (23%)
and 699 chemotherapy-based (77%) regimens. Antithymo-
cyte globulin was administered to 317 patients (35%), and
alemtuzumab was given to 73 patients (8%).
Missing KIR Ligand Model
For AML patients, there were no signiﬁcant ﬁndings in
any of the post-transplant outcomes when comparing re-
cipients with all KIR ligands (n¼ 217) versus those lacking C1
ligand only (n¼ 136) versus those lacking C2 ligand only (n¼
59) versus those lacking Bw4 ligand only (n ¼ 80) versus
those lacking both Bw4 and C1 or C2 ligands (n ¼ 120).
Similarly, no associations with outcomes were observed us-
ing this approach for patients with MDS. Risk for acute GVHD
was higher among AML patients lacking KIR ligands after
adjusting for other clinical factors. In particular, patients
lacking 1 or more KIR ligands (n ¼ 393) experienced higher
grades III to IV acute GVHD (hazard ratio [HR], 1.6; 95%
conﬁdence interval [CI], 1.16 to 2.28; P ¼ .005) compared to
those with all KIR ligands present (n ¼ 217) (Table 2). The
100-day and 1-year adjusted cumulative incidence rates
were 29% (range, 25% to 34%) versus 20% (range, 16% to 26%)
(P ¼ .013) and 31% (range, 27% to 36%) versus 21% (range, 16%
to 27%) (P ¼ .004), respectively. No other outcomes were
signiﬁcant for AML or MDS when comparing transplant re-
cipients with all inhibitory KIR ligands present to those
lacking at least 1.
Pairwise comparisons between absence and presence of
speciﬁc inhibitory HLA-KIR ligands were next considered. In
a multivariate analysis, AML patients lacking HLA-C2 for
donor KIR2DL1 (n ¼ 248) experienced higher grade II to IV
(HR, 1.4; 95% CI, 1.1 to 1.7; P ¼ .002) and III to IV acute GVHD
(HR, 1.5; 95% CI, 1.1 to 2.0; P ¼ .01) compared with those in
whom the ligand was present (n ¼ 361) (Table 3). The
respective 100-day and 1-year adjusted cumulative inci-
dence rates for grade II to IV acute GVHD were 59% (range,
53% to 65%) versus 48% (range, 43% to 52%) (P ¼ .004) and
63% (range, 57% to 68%) versus 51% (range, 46% to 56%) (P ¼
.002) and for grade III to IV acute GVHDwere 31% (range, 25%
to 36%) versus 23% (range, 19% to 28%) (P ¼ .04) and 33%
(range, 27% to 39%) versus 24% (range, 20% to 29%) (P ¼ .02).
When patients who had received alemtuzumab (n ¼ 53)
were excluded, absence of HLA-C2 continued to be associ-
ated with higher grade II to IV (HR, 1.4; 95% CI, 1.13 to 1.76;
P¼ .003) and III to IV acute GVHD (HR,1.5; 95% CI,1.12 to 2.11;
P ¼ .007). There were no differences in baseline character-
istics between patients with or without HLA-C2 (Table 1).
For the combined AML and MDS patient cohort lack of
HLA-C2 (n ¼ 367) was associated with increased grade II to
IV (HR, 1.3; 95% CI, 1.1 to 1.6; P ¼ .005) and III to IV acute
GVHD (HR, 1.5; 95% CI, 1.2 to 1.9; P ¼ .002). However, no
signiﬁcant association of lack of HLA-C2 with grades II to IV
or III to IV acute GVHD was observed in MDS patients alone
(HR, 1.1; 95% CI, .77 to 1.5; P ¼ .71 and HR, 1.5; 95% CI, .94 to
2.9; P ¼ .09, respectively). There were no differences in
chronic GVHD, relapse, TRM, DFS, and overall survival
Table 1
Characteristics of Study Subjects by Recipient C2 Ligand Status
Variable C2 Negative N (%) C2 Positive N (%) P
Number of patients 368 541
Number of centers 82 86
Median age, yr (range) 56 (20-74) 57 (20-74) .54
Age at transplant .13
20-29 yr 13 (4) 32 (6)
30-39 yr 32 (9) 31 (6)
40-49 yr 63 (17) 86 (16)
50þ yr 260 (71) 392 (72)
Recipient race/ethnicity .15
White race, non-Hispanic 336 (95) 492 (93)
African American race, non-Hispanic 3 (1) 17 (3)
Asian race, non-Hispanic 1 (<1) 3 (1)
Native American race, non-Hispanic 0 1 (<1)
Hispanic, white race 13 (4) 16 (3)
Other/multiple 1 (<1) 0
Missing 14 12
Male sex 214 (58) 305 (56) .60
Karnofsky score before transplant
<90 129 (35) 173 (32) .38
90 196 (53) 313 (58)
Missing 43 (12) 55 (10)
HLA matching .25
8/8 294 (80) 418 (77)
7/8 MM at HLA-A 23 (6) 39 (7)
7/8 MM at HLA-B 8 (2) 26 (5)
7/8 MM at HLA-C 41 (11) 53 (10)
7/8 MM at HLA-DRB1 2 (1) 5 (1)
Disease at transplant .86
AML 249 (68) 363 (67)
MDS 119 (32) 178 (33)
Received ATG 116 (32) 201 (37) .08
Received Alemtuzumab 26 (7) 47 (9) .40
Disease status at transplant .49
Early 160 (43) 217 (40)
Intermediate 57 (15) 77 (14)
Advanced 125 (34) 197 (36)
Missing 26 (7) 50 (9)
Conditioning regimen .60
TBI 200 cGy 7 (2) 4 (1)
Fludarabine þ TBI 72 (20) 98 (18)
Fludarabine þ Cy 32 (9) 51 (9)
Fludarabine þ melphalan 100 (27) 139 (26)
Fludarabine þ busulfan þ ATG 112 (30) 195 (36)
Fludarabine þ busulfan (no ATG) 41 (12) 49 (9)
Thiotepa þ Cy þ ATG 4 (1) 5 (1)
GVHD prophylaxis .94
CsA þ MTX 16 (4) 25 (5)
CsA þ MMF 63 (17) 96 (18)
CsA  other (no MTX and no MMF) 13 (4) 13 (2)
Tacrolimus þ MTX 121 (33) 177 (33)
Tacrolimus þ MMF 92 (25) 139 (26)
Tacrolimus  other (no MTX and no MMF) 25 (7) 45 (9)
T cell depletion 38 (10) 46 (9)
Stem cell source .78
Bone marrow 70 (19) 99 (18)
Peripheral blood progenitor cells 298 (81) 442 (82)
Donorerecipient sex match .10
Maleemale 165 (45) 214 (40)
Maleefemale 99 (27) 131 (24)
Femaleemale 48 (13) 91 (17)
Femaleefemale 56 (15) 105 (19)
Donorerecipient CMV match .14
Negativeenegative 91 (25) 150 (28)
Negativeepositive 156 (42) 184 (34)
Positiveenegative 37 (10) 57 (11)
Positiveepositive 77 (21) 136 (25)
Unknown 7 (2) 14 (3)
Median donor age, yr (range) 34 (18-59) 35 (18-61) .20
Donor age .32
18-19 yr 9 (2) 9 (2)
20-29 yr 112 (30) 158 (29)
30-39 yr 136 (37) 197 (36)
(Continued on next page)
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Table 1
(continued)
Variable C2 Negative N (%) C2 Positive N (%) P
40-49 yr 91 (25) 128 (24)
50þ yr 20 (5) 49 (9)
Median interval from diagnosis to transplant, mo (range)
AML 6 (1.0-90) 7 (.5-69) .22
MDS 10 (.6-186) 10 (1-270) .44
Year of transplant .15
1999 4 (1) 4 (1)
2000 14 (4) 11 (2)
2001 28 (8) 27 (5)
2002 17 (5) 33 (6)
2003 36 (10) 50 (9)
2004 64 (17) 70 (13)
2005 70 (19) 116 (21)
2006 92 (25) 150 (28)
2007 43 (12) 80 (15)
Median follow-up of survivors, mo (range) 63 (5-133) 58 (4-121) .009*
ATG indicates antithymocyte globulin; TBI, total body irradiation; CY, cyclophosphamide; CsA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate
mofetil; CMV, cytomegalovirus.
* Log-rank P value.
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Furthermore, there were no differences in any of the out-
comes for AML or MDS when comparing the absence and
presence of HLA-C1 ligand for KIR2DL2/KIR2DL3. No associ-
ations with outcomes were observed when considering
absence of HLA-Bw4 ligand for patients with AML (Table 4)
or MDS.
Donor Tcell chimerismwas assessed for 608 patients (403
AML and 205 MDS) at days þ30, þ100, þ183, and þ365. No
associationwas observed for achievement of complete donor
T cell chimerism when comparing donors with all ligands
present versus those missing 1 or more KIR ligands.Assessment of Individual Donor-Activating KIRs
Pairwise comparisons between the absence and presence
of each donor-activating KIR (KIR2DS1, KIR2DS2, KIR2DS3,
KIR2DS4, KIR2DS5, and KIR3DS1) independent of the others
did not identify differences in any of the study endpoints.
However, when assessing AML patients with KIR2DS1þTable 2
Multivariate Analysis of Recipient KIR Ligands for AML Only
Recipient KIR Ligands All Present 1 Absent P
N Reference N HR (95% CI)
Overall survival* 217 1.00 395 1.04 (.85-1.28) .69
DFSy 217 1.00 395 .93 (.75-1.15) .49
TRMz 213 1.00 390 1.43 (1.01-2.01) .04
Relapsex 215 1.00 394 .81 (.62-1.05) .11
Acute GVHD grades II-IVk 217 1.00 392 1.22 (.97-1.53) .09
Acute GVHD grades III-IV{ 217 1.00 393 1.63 (1.16-2.28) .005
Chronic GVHD# 208 1.00 387 1.07 (.84-1.37) .59
* Adjusted for disease stage, donorerecipient CMV matching, GVHD
prophylaxis, recipient race/ethnicity, and stratiﬁed by graft type.
y Adjusted for disease stage and stratiﬁed by graft type, donorerecipient
CMV matching, and Karnofsky score.
z Adjusted for recipient race/ethnicity, donorerecipient sex matching,
conditioning regimen, GVHD prophylaxis, time from diagnosis to transplant,
and stratiﬁed by graft type.
x Adjusted for disease stage and time from diagnosis to transplant and
stratiﬁed by conditioning regimen and Karnofsky score.
k Adjusted for graft type, GVHD prophylaxis, recipient race, and stratiﬁed
by use of alemtuzumab.
{ Adjusted for HLA matching, recipient race/ethnicity, GVHD prophylaxis,
and Karnofsky score.
# Adjusted for in vivo T cell depletion, conditioning regimen, GVHD pro-
phylaxis, and stratiﬁed by recipient CMV status.donors, those with C2/C2 backgrounds (n ¼ 33) were asso-
ciated with greater TRM compared with those with C1
backgrounds (n ¼ 189) or with KIR2DS1 donors (n ¼ 390)
(HR, 2.4; 95% CI, 1.4 to 4.2; P ¼ .002; Figure 1). The 100-day
and 1-year adjusted cumulative incidence rates of TRM
were 26% (range,12% to 40%) versus 9% (range, 6% to 11%) (P¼
.017) and 40% (range, 25% to 56%) versus 20% (range, 17% to
23%) (P ¼ .011), respectively. There were no signiﬁcant dif-
ferences in characteristics or in the causes of TRM between
the groups. The causes of TRM for those with KIR2DS1þ do-
nors and C2/C2 backgrounds included 9 AML, 4 idiopathic
pneumonia syndrome, 4 other organ failure, 4 infection, and
3 GVHD. This association of increased TRM was not observed
for those with MDS. No other study endpoints were found to
be signiﬁcant for AML or MDS when segregating KIR2DS1þ
donors by their C1 versus C2/C2 backgrounds.
Donor Centromeric KIR Content
Donor-activating KIRs were assessed and categorized as
homozygous for the cen-B haplotype (cenBB; 57 for AML andTable 3
Multivariate Analysis of Recipient C2 Ligand for AML Only
Recipient C2 Ligand Status Present Absent P
N Reference N HR (95% CI)
Overall survival* 363 1.00 249 1.08 (.88-1.32) .48
DFSy 363 1.00 249 1.00 (.82-1.23) .97
TRMz 358 1.00 245 1.22 (.90-1.67) .20
Relapsex 361 1.00 248 .94 (.72-1.23) .69
Acute GVHD grades II-IVk 361 1.00 248 1.41 (1.12-1.72) .002
Acute GVHD grades III-IV{ 362 1.00 248 1.47 (1.09-2.00) .01
Chronic GVHD# 353 1.00 242 .95 (.74-1.22) .68
* Adjusted for disease stage, donorerecipient CMV matching, GVHD
prophylaxis, recipient race/ethnicity, and stratiﬁed by graft type.
y Adjusted for disease stage and stratiﬁed by graft type, donorerecipient
CMV matching, and Karnofsky score.
z Adjusted for recipient race/ethnicity, donorerecipient sex matching,
conditioning regimen, GVHD prophylaxis, time from diagnosis to transplant,
and stratiﬁed by graft type.
x Adjusted for disease stage and time from diagnosis to transplant and
stratiﬁed by conditioning regimen and Karnofsky score.
k Adjusted for graft type, GVHD prophylaxis, recipient race, and stratiﬁed
by use of alemtuzumab.
{ Adjusted for HLA matching, recipient race/ethnicity, GVHD prophylaxis
and Karnofsky score.
# Adjusted for in vivo T cell depletion, conditioning regimen, GVHD pro-
phylaxis, and stratiﬁed by recipient CMV status.
Table 4
Multivariate Analysis of Recipient Bw4 Ligand for AML Only
Recipient Bw4 Ligand Status Present Absent P
N Reference N HR (95% CI)
Overall survival* 433 1.00 179 .96 (.78-1.19) .69
DFSy 433 1.00 179 .87 (.69-1.09) .21
TRMz 427 1.00 176 1.15 (.83-1.59) .41
Relapsex 430 1.00 179 .76 (.56-1.03) .07
aGVHD II-IVk 433 1.00 176 .96 (.76-1.22) .75
aGVHD III-IV{ 433 1.00 177 1.25 (.90-1.72) .18
cGVHD# 420 1.00 175 .94 (.73-1.22) .68
* Adjusted for disease stage, donorerecipient CMV matching, GVHD
prophylaxis, recipient race/ethnicity, and stratiﬁed by graft type.
y Adjusted for disease stage and stratiﬁed by graft type, donorerecipient
CMV matching, and Karnofsky score.
z Adjusted for recipient race/ethnicity, donorerecipient sex matching,
conditioning regimen, GVHD prophylaxis, time from diagnosis to transplant,
and stratiﬁed by graft type.
x Adjusted for disease stage and time from diagnosis to transplant and
stratiﬁed by conditioning regimen and Karnofsky score.
k Adjusted for graft type, GVHD prophylaxis, recipient race, and stratiﬁed
by use of alemtuzumab.
{ Adjusted for HLA matching, recipient race/ethnicity, GVHD prophylaxis,
and Karnofsky score.
# Adjusted for in vivo T cell depletion, conditioning regimen, GVHD pro-
phylaxis, and stratiﬁed by recipient CMV status.
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298 for AML and 145 for MDS), or heterozygous cen-AB (255
for AML and 128 for MDS). There were no signiﬁcant differ-
ences in acute or chronic GVHD, relapse, TRM, DFS, and
overall survival between the donor cenBB, cenAA, and cenAB
haplotypes for AML or MDS. In addition, there were no sig-
niﬁcant associations between donor overall B haplotype KIR
content and RIC HCT outcomes.DISCUSSION
In this large series, speciﬁc donorerecipient KIReHLA
combinations are associated with post-transplant outcomes
after RIC HCT for AML. Interestingly, combinations associated
with reduced relapse in myeloablative HCT were not asso-
ciated with protection from relapse in this RIC HCT cohort.
The absence of HLA ligands for donor-inhibitory KIRs and the
presence of activating KIRs are associatedwith a lower risk of
relapse in myeloablative HCT [9,10,24], but the effect of these
genetic conditions on relapse in RIC HCT did not reach sta-
tistical signiﬁcance in our analysis for AML or MDS alone.
Several factors may have contributed to the evident lack
of KIR effect on relapse in this cohort. Compared withFigure 1. TRM for AML patients with donors KIR2DS1þ with a C2C2 back-
ground versus KIR2DS1 or KIR2DS1þ with any C1.previously published studies in myeloablative HCT [15,19],
this more contemporary RIC HCT cohort contained more
peripheral blood progenitor cells than bone marrow as a
graft source. Although the mechanism is unclear, the missing
ligand effect has been more reported in HCT with a bone
marrow stem cell source [9]. However, missing KIR ligand
has had no signiﬁcant impact on transplantation outcome
after nonmyeloablative HCT [34]. Characteristics associated
with a RIC regimen and the patients treated with the
regimen may also obscure possible KIReHLA effects.
Although better tolerated, the lower intensity of chemo-
therapy in RIC HCT may also be less effective than myeloa-
blative conditioning at leukemic clearance, leaving a higher
leukemic burden for immune-mediated leukemic clearance
and a less successful outcome [35,36]. Most patients in this
cohort were older than 50, and older age is associated with
higher risk leukemia, as evidenced by the high percentage of
patients transplanted with advanced disease in this cohort.
Furthermore, older patients may have had unrecognized or
under-reported antecedent hematologic diseases that
inherently have higher risk for relapse post-transplant.
Because AML and MDS represent different disease pop-
ulations and NK effects against MDS are unclear, the analyses
for KIReHLA combinations were performed separately for
each disease. However, any NK cellemediated effect on GVL
may have been mitigated in the AML study population,
which included 30% of patients with a prior MDS or other
antecedent hematologic disorder. Combined, these factors
may explain the apparent lack of KIReHLA effect in this RIC
HCT cohort.
Lack of data regarding cytogenetic risk groups in the
registry is a limitation of this study. If differences in the
proportion with poor-risk cytogenetics existed between the
KIReHLA combinations we analyzed, this may also have
confounded a NK cellemediated GVL effect. Furthermore,
although our analysis was adjusted for GVHD prophylaxis,
differences between RIC approaches regarding duration of
immunosuppressant therapy or antibody dosing for in vivo T
cell depletion may have also impacted relapse and other
outcomes.
We observed the combination of donor KIR2DS1 with
HLA-C2/C2 in the donor was associated with higher TRM in
AML patients. In vitro evidence suggests that NK cell reac-
tivity is decreased for KIR2DS1 in the presence of high
amounts of HLA-C2 ligand [37-40]. This combination has
been associated with a diminished capacity to control AML
relapse after myeloablative transplant conditioning [15]. We
were unable to appreciate such an effect on relapse in the
current series of RIC transplants, possibly related to the small
number of patients with such donors. Furthermore, no sur-
vival beneﬁt or reduction in acute GVHD was observed for
those with donors positive for KIR3DS1 in this RIC study
population in contrast to this reported association for mye-
loablative HCT [14,15].
Donor cen-B KIR haplotypes have been reported to
contribute to relapse protection and improved survival after
T cellereplete myeloablative HCT for AML, where homozy-
gosity for the cen-B partial haplotype had the strongest in-
dependent effect [18]. Contrasting results, however, have
been found in T celledepleted HCT [41]. Haplotype B/x do-
nors have also been associated with a higher incidence of
chronic GVHD [13]. In the RIC HLA-haploidentical transplant
setting, a KIR haplotype B donor has been associated with
lower risk of relapse for patients with hematologic malig-
nancies [42]. We found that in RIC HCT for AML and MDS,
R.M. Sobecks et al. / Biol Blood Marrow Transplant 21 (2015) 1589e1596 1595donor homozygosity for the cen-B haplotype does not have a
signiﬁcant impact in leukemia relapse, overall survival, TRM,
or GVHD.
We observed that recipients lacking  1 KIR ligands, in
particular those lacking HLA-C2 ligand for donor-inhibitory
KIR2DL1, were associated with increased acute GVHD.
Although acute GVHD has previously been reported to be
associated with a missing KIR ligand, including HLA-C2
ligand [9,43-45], we did not observe increased acute GVHD
for RIC HCT with regard to AA haplotypes as previously re-
ported [44,46,47]. For those patients with HLA-C disparate
donors, increased expression levels of the mismatched HLA-
C allotypemay also have increased the risks of grades III to IV
acute GVHD, as recently reported [48]. In contrast to prior
myeloablative HCT studies, patients treated with RIC in this
series were older and more commonly received peripheral
blood progenitor cells and T cellereplete grafts, factors that
may have inﬂuenced the development of acute GVHD.
The precise mechanism underlying these KIR associations
with GVHD remains elusive. Increased NK cell IFN-g pro-
duction has been correlated with acute GVHD [49]; however,
donor NK lysis of recipient antigen-presenting cells abro-
gates GVHD [3]. Clearly, more studies are needed to delineate
how NK and T cell interaction, either direct or indirect
through cytokine-mediated changes, affects GVHD.
KIReHLA ligand matching has been reported to inﬂuence
achievement of T cellecomplete donor chimerism after
nonmyeloablative related donor HCT performed for many
different diseases [50]. The current report restricted to AML
and MDS patients undergoing URD RIC HCT is, to our
knowledge, the largest experience of T cell chimerism in this
transplant setting. Donor KIR ligand absence was not asso-
ciated with the development of T cellecomplete donor
chimerism.
Our results suggest that speciﬁc donorerecipient
KIReHLA interactions are associated with post-transplant
outcomes after RIC-URD HCT for AML. The unfavorable as-
sociation of lack of HLA-C2 for donor KIR2DL1 and GVHD are
useful for discussions of prognosis. The ﬁnding that donor
HLA-C2 homozygosity and KIR2DS1 is associated with higher
TRM suggests this should also be considered when selecting
donors. In light of previous ﬁndings that HLA-C2 homozy-
gosity is associated with higher risk for relapse [15,22], se-
lection of an HLA-Cmismatched donor in preference to other
mismatched donors at other HLA loci may be justiﬁed. Donor
selection based on activating KIR proﬁle otherwise was not
supported by this study, which did not demonstrate salutary
effects of donor-activating KIR, particularly those located in
the centromeric portion of the KIR haplotype.
Investigation of larger cohorts of more homogeneous
patient populations and functional studies are warranted to
help further assess the inﬂuence of KIReHLA combinations
on outcomes after RIC HCT. In addition, most patients in this
series were white. Future prospective studies of KIR-
mediated effects in RIC HCT should ideally be performed
with ethnically diverse populations to better assess for dif-
ferences in outcomes among speciﬁc ethnic subsets. Further
elucidation of the biology of NK cell alloreactivity in the RIC
setting may also provide guidance for future approaches to
help optimize conditions for generating GVL activity without
GVHD and for minimizing TRM in this transplant population.
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